Partnerships
Brain shuttle technology has become one of the most strategically sought assets in drug development. Leading pharmaceutical companies are securing access to proven delivery platforms early, even before beginning clinical work, recognizing that brain delivery infrastructure is a long-term competitive advantage. NucleoTech’s BrainPortal™ carriers are built for exactly this moment.
We are selective about the partnerships we pursue. Our focus is on working with serious programs where our carriers can make a meaningful difference, and where partners bring the conviction and resources to advance a program to its full potential. We bring validated delivery assets and a proprietary discovery platform to every partnership, enabling collaborative structures that create value for both sides.
We partner across multiple models depending on the program and partner needs. Explore the options below or get in touch to discuss what makes sense for your program.
Carrier Licensing
NucleoTech licenses its proprietary BrainPortal™ carriers, including our lead asset P28, to pharma and biotech partners developing therapeutics that need brain delivery. Our carriers are validated across multiple species and compatible with antibody and oligonucleotide modalities, providing partners with a reliable, best-in-class delivery solution they can build a program around. Licensing terms are structured to fit the partner's program and commercial context. For partners with programs blocked by the BBB who need a validated delivery solution.
Therapeutic Partnering
NucleoTech is advancing an internal portfolio of brain-deliverable therapeutics built on validated drug backbones and proprietary BrainPortal™ carriers. At the right stage and with the right partner, we are open to collaborative structures that help accelerate and expand the reach of these programs. We welcome conversations with partners who bring clinical, regulatory, or commercial expertise that complements our delivery and discovery capabilities. For partners looking to build alongside compelling CNS assets with de-risked biology.
Joint Development
For select partners developing new therapeutic candidates from early stages, NucleoTech offers bespoke carrier engineering and screening, identifying the best-performing BrainPortal™ carrier for a specific drug candidate and advancing the combination through preclinical validation together. This is an opportunistic model reserved for programs where the science is compelling and the partnership is strategically aligned. For partners building new brain-deliverable therapeutics who want NucleoTech's platform integrated from day one.
Why NucleoTech
NucleoTech brings validated, best-in-class delivery assets and a proprietary discovery platform that continues to identify and optimize new carriers at speed.
Our direct in vivo platform means carrier development and optimization can happen on a timeline that fits a partner's program, not the other way around.